Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation

The viral ribonucleotide reductase (rR)-defective herpes simplex type-1 (HSV-1) virus (hrR3) has been shown previously to preferentially replicate in and kill tumor cells. This selectivity is associated with tumor cell up-regulation of mammalian rR. Ionizing radiation (IR) is currently used in the t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer gene therapy 2000-07, Vol.7 (7), p.1051-1059
Hauptverfasser: Spear, M A, Sun, F, Eling, D J, Gilpin, E, Kipps, T J, Chiocca, E A, Bouvet, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1059
container_issue 7
container_start_page 1051
container_title Cancer gene therapy
container_volume 7
creator Spear, M A
Sun, F
Eling, D J
Gilpin, E
Kipps, T J
Chiocca, E A
Bouvet, M
description The viral ribonucleotide reductase (rR)-defective herpes simplex type-1 (HSV-1) virus (hrR3) has been shown previously to preferentially replicate in and kill tumor cells. This selectivity is associated with tumor cell up-regulation of mammalian rR. Ionizing radiation (IR) is currently used in the therapy of many malignancies, including glioblastoma, cervical carcinoma, and pancreatic carcinoma. IR has been shown to up-regulate mammalian rR in tumor cells and appears to increase the efficacy of at least one non-rR-deleted HSV-1 strain in an in vivo tumor model. Here, we test the hypothesis that a single therapeutic radiation fraction will increase the replication and toxicity of hrR3 for malignant cell lines in vitro. PANC-1 pancreatic carcinoma, U-87 glioblastoma, and CaSki cervical carcinoma cell lines were treated with varying doses of IR and subsequently infected with hrR3 or KOS (wild-type HSV-1 strain). Cell survival was then measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and trypan blue exclusion cytometry. At 72 hours posttreatment, irradiation with 2 Gy reduced survival from 100% to 76% in noninfected cells, from 61% to 48% in KOS-infected cells, and from 39% to 27% in hrR3-infected PANC-1 cells. As such, analysis of variance indicated that the toxicity of the two modalities was additive. Similar additivity was seen in U-87 MG and CaSki cells. Absolute survival of hrR3-infected or KOS-infected PANC-1 cells decreased as a function of time after treatment (24-72 hours) and multiplicity of infection (MOI) (0.05-5.0). However, the relative decrease in survival with the addition of IR to hrR3 or KOS in PANC-1 cells was not markedly affected by altering MOI (0.05-5.0), time (24-72 hours), radiation dose (2-20 Gy), or cell culture conditions (confluent/growth arrested). We used fluorescence-activated cell sorter analysis with the cationic lipophilic dye DiOC6 to quantify a reduction in mitochondrial membrane potential that'is associated with apoptosis. Fluorescence-activated cell sorter analysis indicated increased apoptosis in both hrR3- and IR-treated cells at 48-72 hours, with hrR3 alone producing the most induction. Viral yields from PANC-1 cells after irradiation and infection were examined. No significant differences were seen between irradiated and nonirradiated cells in viral replication, with hrR3 producing single-step titers of 3.1 +/- 0.9 x 10(5) and 4.0 +/- 1.2 x 10(5) plaque-forming units/mL in nonirra
doi_str_mv 10.1038/sj.cgt.7700208
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18179640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>998143391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-cbaf6a07b6e42c5fa31e722705ab386b1ca2c247a7706e94ce1fffde1f21819a3</originalsourceid><addsrcrecordid>eNp1kdGL1DAQxoMo3nr66qMEBVGwaybtNu2jLOodHAiizyFNp7eztE1N0vPqv3b_nFl3D0TwZTIwv3zfJB9jz0GsQeTV-7Bf2-u4VkoIKaoHbAWFKrPNRoiHbCVqWWdQi_yMPQlhL0QaqvwxOwNRg0r8it1tl-iiuyVLcXnHzeSm6AKF1I4tvyFveu5x6smaSG7kNPI4D85zi30fePRoIrb8J8Udd6N1_RLJck-NG2fbo4vUYhJoZxtNwKzFDm2kG-Q79BMGHmiYerzlcZmQw8FwDvzNzn_N33LrhobGe_XkTr9ovObetPRnmafsUWf6gM9O5zn7_unjt-1FdvXl8-X2w1Vmc6ViZhvTlUaopsRC2k1nckAlpRIb0-RV2YA10spCmfSJJdaFRei6rk1VQgW1yc_Z66Pu5N2PGUPUA4XD-82Ibg46UaouC5HAV_-Aezf7Me2mZVmAAhBwoF7-lwJVVFCqKkHrI2S9C8FjpydPg_GLBqEPyeuw1yl5fUo-XXhxUp2bAdu_8GPU-W_0sa70</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217481678</pqid></control><display><type>article</type><title>Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerNature Journals</source><creator>Spear, M A ; Sun, F ; Eling, D J ; Gilpin, E ; Kipps, T J ; Chiocca, E A ; Bouvet, M</creator><creatorcontrib>Spear, M A ; Sun, F ; Eling, D J ; Gilpin, E ; Kipps, T J ; Chiocca, E A ; Bouvet, M</creatorcontrib><description>The viral ribonucleotide reductase (rR)-defective herpes simplex type-1 (HSV-1) virus (hrR3) has been shown previously to preferentially replicate in and kill tumor cells. This selectivity is associated with tumor cell up-regulation of mammalian rR. Ionizing radiation (IR) is currently used in the therapy of many malignancies, including glioblastoma, cervical carcinoma, and pancreatic carcinoma. IR has been shown to up-regulate mammalian rR in tumor cells and appears to increase the efficacy of at least one non-rR-deleted HSV-1 strain in an in vivo tumor model. Here, we test the hypothesis that a single therapeutic radiation fraction will increase the replication and toxicity of hrR3 for malignant cell lines in vitro. PANC-1 pancreatic carcinoma, U-87 glioblastoma, and CaSki cervical carcinoma cell lines were treated with varying doses of IR and subsequently infected with hrR3 or KOS (wild-type HSV-1 strain). Cell survival was then measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and trypan blue exclusion cytometry. At 72 hours posttreatment, irradiation with 2 Gy reduced survival from 100% to 76% in noninfected cells, from 61% to 48% in KOS-infected cells, and from 39% to 27% in hrR3-infected PANC-1 cells. As such, analysis of variance indicated that the toxicity of the two modalities was additive. Similar additivity was seen in U-87 MG and CaSki cells. Absolute survival of hrR3-infected or KOS-infected PANC-1 cells decreased as a function of time after treatment (24-72 hours) and multiplicity of infection (MOI) (0.05-5.0). However, the relative decrease in survival with the addition of IR to hrR3 or KOS in PANC-1 cells was not markedly affected by altering MOI (0.05-5.0), time (24-72 hours), radiation dose (2-20 Gy), or cell culture conditions (confluent/growth arrested). We used fluorescence-activated cell sorter analysis with the cationic lipophilic dye DiOC6 to quantify a reduction in mitochondrial membrane potential that'is associated with apoptosis. Fluorescence-activated cell sorter analysis indicated increased apoptosis in both hrR3- and IR-treated cells at 48-72 hours, with hrR3 alone producing the most induction. Viral yields from PANC-1 cells after irradiation and infection were examined. No significant differences were seen between irradiated and nonirradiated cells in viral replication, with hrR3 producing single-step titers of 3.1 +/- 0.9 x 10(5) and 4.0 +/- 1.2 x 10(5) plaque-forming units/mL in nonirradiated and irradiated cells. Thus, complementary toxicity was seen between IR and hrR3 or KOS, regardless of cell type, time, MOI, IR dose, or culture conditions, without evidence of augmented apoptosis or viral replication.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/sj.cgt.7700208</identifier><identifier>PMID: 10917208</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Apoptosis ; Cell culture ; Cell Survival ; Cervical cancer ; Cervical carcinoma ; Cervix ; Combined Modality Therapy ; Cytometry ; Cytotoxicity ; Defective Viruses ; Female ; Flow Cytometry ; Glioblastoma ; Glioblastoma - radiotherapy ; Glioblastoma - virology ; Glioma ; Herpes simplex ; Herpes simplex virus 1 ; Herpes viruses ; Herpesvirus 1, Human - physiology ; Humans ; Ionizing radiation ; Lipophilic ; Membrane potential ; Mitochondria ; Multiplicity of infection ; Oncolysis ; Pancreatic cancer ; Pancreatic carcinoma ; Pancreatic Neoplasms - radiotherapy ; Pancreatic Neoplasms - virology ; Radiation ; Radiation Dosage ; Radiation, Ionizing ; Replication ; Ribonucleotide reductase ; Ribonucleotide Reductases - metabolism ; Tetrazolium Salts - metabolism ; Thiazoles - metabolism ; Tumor cell lines ; Tumor cells ; Tumor Cells, Cultured - enzymology ; Tumor Cells, Cultured - radiation effects ; Tumor Cells, Cultured - virology ; Uterine Cervical Neoplasms - radiotherapy ; Uterine Cervical Neoplasms - virology ; Virus Replication - physiology</subject><ispartof>Cancer gene therapy, 2000-07, Vol.7 (7), p.1051-1059</ispartof><rights>Copyright Nature Publishing Group Jul 2000</rights><rights>Nature America, Inc. 2000.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-cbaf6a07b6e42c5fa31e722705ab386b1ca2c247a7706e94ce1fffde1f21819a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10917208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spear, M A</creatorcontrib><creatorcontrib>Sun, F</creatorcontrib><creatorcontrib>Eling, D J</creatorcontrib><creatorcontrib>Gilpin, E</creatorcontrib><creatorcontrib>Kipps, T J</creatorcontrib><creatorcontrib>Chiocca, E A</creatorcontrib><creatorcontrib>Bouvet, M</creatorcontrib><title>Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><description>The viral ribonucleotide reductase (rR)-defective herpes simplex type-1 (HSV-1) virus (hrR3) has been shown previously to preferentially replicate in and kill tumor cells. This selectivity is associated with tumor cell up-regulation of mammalian rR. Ionizing radiation (IR) is currently used in the therapy of many malignancies, including glioblastoma, cervical carcinoma, and pancreatic carcinoma. IR has been shown to up-regulate mammalian rR in tumor cells and appears to increase the efficacy of at least one non-rR-deleted HSV-1 strain in an in vivo tumor model. Here, we test the hypothesis that a single therapeutic radiation fraction will increase the replication and toxicity of hrR3 for malignant cell lines in vitro. PANC-1 pancreatic carcinoma, U-87 glioblastoma, and CaSki cervical carcinoma cell lines were treated with varying doses of IR and subsequently infected with hrR3 or KOS (wild-type HSV-1 strain). Cell survival was then measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and trypan blue exclusion cytometry. At 72 hours posttreatment, irradiation with 2 Gy reduced survival from 100% to 76% in noninfected cells, from 61% to 48% in KOS-infected cells, and from 39% to 27% in hrR3-infected PANC-1 cells. As such, analysis of variance indicated that the toxicity of the two modalities was additive. Similar additivity was seen in U-87 MG and CaSki cells. Absolute survival of hrR3-infected or KOS-infected PANC-1 cells decreased as a function of time after treatment (24-72 hours) and multiplicity of infection (MOI) (0.05-5.0). However, the relative decrease in survival with the addition of IR to hrR3 or KOS in PANC-1 cells was not markedly affected by altering MOI (0.05-5.0), time (24-72 hours), radiation dose (2-20 Gy), or cell culture conditions (confluent/growth arrested). We used fluorescence-activated cell sorter analysis with the cationic lipophilic dye DiOC6 to quantify a reduction in mitochondrial membrane potential that'is associated with apoptosis. Fluorescence-activated cell sorter analysis indicated increased apoptosis in both hrR3- and IR-treated cells at 48-72 hours, with hrR3 alone producing the most induction. Viral yields from PANC-1 cells after irradiation and infection were examined. No significant differences were seen between irradiated and nonirradiated cells in viral replication, with hrR3 producing single-step titers of 3.1 +/- 0.9 x 10(5) and 4.0 +/- 1.2 x 10(5) plaque-forming units/mL in nonirradiated and irradiated cells. Thus, complementary toxicity was seen between IR and hrR3 or KOS, regardless of cell type, time, MOI, IR dose, or culture conditions, without evidence of augmented apoptosis or viral replication.</description><subject>Apoptosis</subject><subject>Cell culture</subject><subject>Cell Survival</subject><subject>Cervical cancer</subject><subject>Cervical carcinoma</subject><subject>Cervix</subject><subject>Combined Modality Therapy</subject><subject>Cytometry</subject><subject>Cytotoxicity</subject><subject>Defective Viruses</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Glioblastoma</subject><subject>Glioblastoma - radiotherapy</subject><subject>Glioblastoma - virology</subject><subject>Glioma</subject><subject>Herpes simplex</subject><subject>Herpes simplex virus 1</subject><subject>Herpes viruses</subject><subject>Herpesvirus 1, Human - physiology</subject><subject>Humans</subject><subject>Ionizing radiation</subject><subject>Lipophilic</subject><subject>Membrane potential</subject><subject>Mitochondria</subject><subject>Multiplicity of infection</subject><subject>Oncolysis</subject><subject>Pancreatic cancer</subject><subject>Pancreatic carcinoma</subject><subject>Pancreatic Neoplasms - radiotherapy</subject><subject>Pancreatic Neoplasms - virology</subject><subject>Radiation</subject><subject>Radiation Dosage</subject><subject>Radiation, Ionizing</subject><subject>Replication</subject><subject>Ribonucleotide reductase</subject><subject>Ribonucleotide Reductases - metabolism</subject><subject>Tetrazolium Salts - metabolism</subject><subject>Thiazoles - metabolism</subject><subject>Tumor cell lines</subject><subject>Tumor cells</subject><subject>Tumor Cells, Cultured - enzymology</subject><subject>Tumor Cells, Cultured - radiation effects</subject><subject>Tumor Cells, Cultured - virology</subject><subject>Uterine Cervical Neoplasms - radiotherapy</subject><subject>Uterine Cervical Neoplasms - virology</subject><subject>Virus Replication - physiology</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kdGL1DAQxoMo3nr66qMEBVGwaybtNu2jLOodHAiizyFNp7eztE1N0vPqv3b_nFl3D0TwZTIwv3zfJB9jz0GsQeTV-7Bf2-u4VkoIKaoHbAWFKrPNRoiHbCVqWWdQi_yMPQlhL0QaqvwxOwNRg0r8it1tl-iiuyVLcXnHzeSm6AKF1I4tvyFveu5x6smaSG7kNPI4D85zi30fePRoIrb8J8Udd6N1_RLJck-NG2fbo4vUYhJoZxtNwKzFDm2kG-Q79BMGHmiYerzlcZmQw8FwDvzNzn_N33LrhobGe_XkTr9ovObetPRnmafsUWf6gM9O5zn7_unjt-1FdvXl8-X2w1Vmc6ViZhvTlUaopsRC2k1nckAlpRIb0-RV2YA10spCmfSJJdaFRei6rk1VQgW1yc_Z66Pu5N2PGUPUA4XD-82Ibg46UaouC5HAV_-Aezf7Me2mZVmAAhBwoF7-lwJVVFCqKkHrI2S9C8FjpydPg_GLBqEPyeuw1yl5fUo-XXhxUp2bAdu_8GPU-W_0sa70</recordid><startdate>20000701</startdate><enddate>20000701</enddate><creator>Spear, M A</creator><creator>Sun, F</creator><creator>Eling, D J</creator><creator>Gilpin, E</creator><creator>Kipps, T J</creator><creator>Chiocca, E A</creator><creator>Bouvet, M</creator><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7QO</scope></search><sort><creationdate>20000701</creationdate><title>Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation</title><author>Spear, M A ; Sun, F ; Eling, D J ; Gilpin, E ; Kipps, T J ; Chiocca, E A ; Bouvet, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-cbaf6a07b6e42c5fa31e722705ab386b1ca2c247a7706e94ce1fffde1f21819a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Apoptosis</topic><topic>Cell culture</topic><topic>Cell Survival</topic><topic>Cervical cancer</topic><topic>Cervical carcinoma</topic><topic>Cervix</topic><topic>Combined Modality Therapy</topic><topic>Cytometry</topic><topic>Cytotoxicity</topic><topic>Defective Viruses</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Glioblastoma</topic><topic>Glioblastoma - radiotherapy</topic><topic>Glioblastoma - virology</topic><topic>Glioma</topic><topic>Herpes simplex</topic><topic>Herpes simplex virus 1</topic><topic>Herpes viruses</topic><topic>Herpesvirus 1, Human - physiology</topic><topic>Humans</topic><topic>Ionizing radiation</topic><topic>Lipophilic</topic><topic>Membrane potential</topic><topic>Mitochondria</topic><topic>Multiplicity of infection</topic><topic>Oncolysis</topic><topic>Pancreatic cancer</topic><topic>Pancreatic carcinoma</topic><topic>Pancreatic Neoplasms - radiotherapy</topic><topic>Pancreatic Neoplasms - virology</topic><topic>Radiation</topic><topic>Radiation Dosage</topic><topic>Radiation, Ionizing</topic><topic>Replication</topic><topic>Ribonucleotide reductase</topic><topic>Ribonucleotide Reductases - metabolism</topic><topic>Tetrazolium Salts - metabolism</topic><topic>Thiazoles - metabolism</topic><topic>Tumor cell lines</topic><topic>Tumor cells</topic><topic>Tumor Cells, Cultured - enzymology</topic><topic>Tumor Cells, Cultured - radiation effects</topic><topic>Tumor Cells, Cultured - virology</topic><topic>Uterine Cervical Neoplasms - radiotherapy</topic><topic>Uterine Cervical Neoplasms - virology</topic><topic>Virus Replication - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spear, M A</creatorcontrib><creatorcontrib>Sun, F</creatorcontrib><creatorcontrib>Eling, D J</creatorcontrib><creatorcontrib>Gilpin, E</creatorcontrib><creatorcontrib>Kipps, T J</creatorcontrib><creatorcontrib>Chiocca, E A</creatorcontrib><creatorcontrib>Bouvet, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spear, M A</au><au>Sun, F</au><au>Eling, D J</au><au>Gilpin, E</au><au>Kipps, T J</au><au>Chiocca, E A</au><au>Bouvet, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation</atitle><jtitle>Cancer gene therapy</jtitle><addtitle>Cancer Gene Ther</addtitle><date>2000-07-01</date><risdate>2000</risdate><volume>7</volume><issue>7</issue><spage>1051</spage><epage>1059</epage><pages>1051-1059</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>The viral ribonucleotide reductase (rR)-defective herpes simplex type-1 (HSV-1) virus (hrR3) has been shown previously to preferentially replicate in and kill tumor cells. This selectivity is associated with tumor cell up-regulation of mammalian rR. Ionizing radiation (IR) is currently used in the therapy of many malignancies, including glioblastoma, cervical carcinoma, and pancreatic carcinoma. IR has been shown to up-regulate mammalian rR in tumor cells and appears to increase the efficacy of at least one non-rR-deleted HSV-1 strain in an in vivo tumor model. Here, we test the hypothesis that a single therapeutic radiation fraction will increase the replication and toxicity of hrR3 for malignant cell lines in vitro. PANC-1 pancreatic carcinoma, U-87 glioblastoma, and CaSki cervical carcinoma cell lines were treated with varying doses of IR and subsequently infected with hrR3 or KOS (wild-type HSV-1 strain). Cell survival was then measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and trypan blue exclusion cytometry. At 72 hours posttreatment, irradiation with 2 Gy reduced survival from 100% to 76% in noninfected cells, from 61% to 48% in KOS-infected cells, and from 39% to 27% in hrR3-infected PANC-1 cells. As such, analysis of variance indicated that the toxicity of the two modalities was additive. Similar additivity was seen in U-87 MG and CaSki cells. Absolute survival of hrR3-infected or KOS-infected PANC-1 cells decreased as a function of time after treatment (24-72 hours) and multiplicity of infection (MOI) (0.05-5.0). However, the relative decrease in survival with the addition of IR to hrR3 or KOS in PANC-1 cells was not markedly affected by altering MOI (0.05-5.0), time (24-72 hours), radiation dose (2-20 Gy), or cell culture conditions (confluent/growth arrested). We used fluorescence-activated cell sorter analysis with the cationic lipophilic dye DiOC6 to quantify a reduction in mitochondrial membrane potential that'is associated with apoptosis. Fluorescence-activated cell sorter analysis indicated increased apoptosis in both hrR3- and IR-treated cells at 48-72 hours, with hrR3 alone producing the most induction. Viral yields from PANC-1 cells after irradiation and infection were examined. No significant differences were seen between irradiated and nonirradiated cells in viral replication, with hrR3 producing single-step titers of 3.1 +/- 0.9 x 10(5) and 4.0 +/- 1.2 x 10(5) plaque-forming units/mL in nonirradiated and irradiated cells. Thus, complementary toxicity was seen between IR and hrR3 or KOS, regardless of cell type, time, MOI, IR dose, or culture conditions, without evidence of augmented apoptosis or viral replication.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>10917208</pmid><doi>10.1038/sj.cgt.7700208</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0929-1903
ispartof Cancer gene therapy, 2000-07, Vol.7 (7), p.1051-1059
issn 0929-1903
1476-5500
language eng
recordid cdi_proquest_miscellaneous_18179640
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerNature Journals
subjects Apoptosis
Cell culture
Cell Survival
Cervical cancer
Cervical carcinoma
Cervix
Combined Modality Therapy
Cytometry
Cytotoxicity
Defective Viruses
Female
Flow Cytometry
Glioblastoma
Glioblastoma - radiotherapy
Glioblastoma - virology
Glioma
Herpes simplex
Herpes simplex virus 1
Herpes viruses
Herpesvirus 1, Human - physiology
Humans
Ionizing radiation
Lipophilic
Membrane potential
Mitochondria
Multiplicity of infection
Oncolysis
Pancreatic cancer
Pancreatic carcinoma
Pancreatic Neoplasms - radiotherapy
Pancreatic Neoplasms - virology
Radiation
Radiation Dosage
Radiation, Ionizing
Replication
Ribonucleotide reductase
Ribonucleotide Reductases - metabolism
Tetrazolium Salts - metabolism
Thiazoles - metabolism
Tumor cell lines
Tumor cells
Tumor Cells, Cultured - enzymology
Tumor Cells, Cultured - radiation effects
Tumor Cells, Cultured - virology
Uterine Cervical Neoplasms - radiotherapy
Uterine Cervical Neoplasms - virology
Virus Replication - physiology
title Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A06%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytotoxicity,%20apoptosis,%20and%20viral%20replication%20in%20tumor%20cells%20treated%20with%20oncolytic%20ribonucleotide%20reductase-defective%20herpes%20simplex%20type%201%20virus%20(hrR3)%20combined%20with%20ionizing%20radiation&rft.jtitle=Cancer%20gene%20therapy&rft.au=Spear,%20M%20A&rft.date=2000-07-01&rft.volume=7&rft.issue=7&rft.spage=1051&rft.epage=1059&rft.pages=1051-1059&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/sj.cgt.7700208&rft_dat=%3Cproquest_cross%3E998143391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217481678&rft_id=info:pmid/10917208&rfr_iscdi=true